Stratifikatsiya riska i strategicheskie resheniya farmakoterapii osteoartroza v terapevticheskoy praktike
- Authors: Naumov A.V1, Vertkin A.L1, Shamuilova M.M1, Semenov P.A1, Mendel' O.I1
-
Affiliations:
- ГОУ ВПО Московский государственный медико-стоматологический университет
- Issue: Vol 11, No 9 (2009)
- Pages: 105-111
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/93104
- ID: 93104
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A. V Naumov
ГОУ ВПО Московский государственный медико-стоматологический университеткафедра клинической фармакологии, фармакотерапии и СМП
A. L Vertkin
ГОУ ВПО Московский государственный медико-стоматологический университеткафедра клинической фармакологии, фармакотерапии и СМП
M. M Shamuilova
ГОУ ВПО Московский государственный медико-стоматологический университеткафедра клинической фармакологии, фармакотерапии и СМП
P. A Semenov
ГОУ ВПО Московский государственный медико-стоматологический университеткафедра клинической фармакологии, фармакотерапии и СМП
O. I Mendel'
ГОУ ВПО Московский государственный медико-стоматологический университеткафедра клинической фармакологии, фармакотерапии и СМП
References
- Cecchi F, Mannoni A et al. Osteoart Cartilage 2008; 16: 1039–46.
- Australian Centre for Complementary Medicine Education & Research, University of Queensland, Brisbane, Australia; Presented at the OARSI 2008 World Congress on Osteoarthritis.
- Boutron I, Rannou F et al. Osteoart Cartilage 2008; 16: 1024–31.
- OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence - based, expert consensus guidelines, 2008.
- Ashley K. Frew, Peter D. Drummond Negative affect, pain and sex: The role of endogenous opioids. Pain 2007; 11: S77–S85.
- White et al. Am J Cardiol 2003; 92: 411–8.
- Rose P, Steinhauser C. Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Posted 05/21/2004.
- Grarup J, Olsen K.J., Danneskiold-Sams?e P, Branebjerg P.E. Clinical Safety Report 1–71. 21декабря 2001; Nycomed.
- Rodriguez L.A. Nonsteroidal Antiinflammatory Drugs, Ulcers and Risk A Collaborative Meta-Analysis [Review]. Seminars in Arthritis & Rheumatism 1997; 26 (6 Suppl. 1): 16–20.
- Hernandez-Diaz S, Rodriguez LAG. Association between nonsteroidal anti - inflammatory drugs and upper gastrointestinal tract bleeding/perforation – An overview of epidemiologic studies published in the 1990s [Review]. Arch Intern Med 2000; 160 (14): 2093–9.
- Walden R.J., Owens C.W.I., Graham B.R. et al. NSAID and the control of hypertension: a pilot study. Brit J Clin Phamracol 1992; 33 (2): 241P.
- Berry H, Bird H.A., Black C et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheumat Dis 1992; 51: 238–42.
- Kidd B, Frenzel W. A multicenter, randomized, double blind study comparing lornoxicam with diclofenac in osteoarthritis. J Rheumatol 1996; 23 (9): 1605–11.
- Whittington J.R. A multicentre, randomised, double - blind, parallel group design comparing the effects of multiple doses of Lornoxicam (Chlortenoxicam) versus Naproxen in patients with osteoarthritis during a three month period followed by a continuation of treatment in an open design in those patients receiving Lornoxicam for a period of six months [later extended to 9 months] (CT 33). Data on File. 30-6-1993. Nycomed.
Supplementary files
